CLINICAL TRIALS PROFILE FOR RABIES VACCINE

All Clinical Trials for rabies vaccine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00031070 ↗	Increasing HAART-Induced Immune Restoration With Cyclosporine	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	The purpose of this study is to see if cyclosporine, taken when a patient begins highly active antiretroviral therapy (HAART), increases the number of CD4 T-cells (blood cells that fight infection) in a patient's blood. This study also will explore the safety of briefly giving cyclosporine to patients starting HAART.
NCT00100646 ↗	Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa	Completed	The Wistar Institute	N/A	2007-03-01	HIV infected people often must take anti-HIV drugs for long periods, leading to long-term drug exposure and toxicity. Interruptions in anti-HIV therapy, also known as structured treatment interruptions (STIs), may have few negative health effects and may be helpful to the overall long-term health of HIV-infected people. The purpose of this study is to determine if sequential short-term STIs of antiretroviral therapy (ART) in HIV infected individuals in a resource-constrained environment can retain the immune reconstitution benefits of continuous treatment while potentially lessening rates of toxicity associated with continuous therapy strategies and at the same time, lessen costs associated with ART.
NCT00740090 ↗	Malaria Vaccine for Children in Mali	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	2008-08-11	This study will evaluate the safety and immune response of children to an experimental malaria vaccine called AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909. Malaria is an infection of red blood cells caused by a parasite, Plasmodium falciparum, that is spread by certain kinds of mosquitoes. It affects at least 300 million people worldwide each year, with more than 1 million deaths, mostly among children less than 5 years of age in sub-Saharan Africa. Malaria is the leading cause of death and illness among the general population of Mali in West Africa. Increasing drug resistance to P. falciparum and widespread resistance of mosquitoes to pesticides are reducing the ability to control the disease through these strategies. AMA1 C1 is made from a synthetic protein similar to a P. falciparum protein. It is combined with Alhydrogel and CPG 7909, substances added to vaccines to make them work better. Children between 1 and 4 years of age who live in Bancoumana, Mali, and are in general good health may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood and urine tests. Participants are randomly assigned to receive three injections (shots) of either AMA1-C1 or a control rabies inactivated vaccine called Imovax® (Registered Trademark). The shots are given in the thigh muscle on study days 0, 56 and 180. After each shot, participants are observed in the clinic for 30 minutes. They return to the clinic for a physical examination six or seven times between each shot and then four more times over a 9-month period after the last shot. Blood samples are drawn at several of these visits to check for side effects of the vaccine and to measure the response to it. The total duration of the study is 21 months. ...
NCT01165645 ↗	Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma	Withdrawn	Mayo Clinic	N/A	2010-11-01	RATIONALE: HIV protease inhibitors, including Lopinavir/Ritonavir have intrinsic anti-apoptotic properties in addition to their anti-viral effect on HIV. This anti-apoptotic effect may boost the immune system to help the body create a better immune response to vaccines. PURPOSE: This randomized clinical trial studies giving lopinavir and ritonavir together in improving immune response to vaccines in patients with complete remission following a bone marrow transplant for Hodgkin lymphoma.
NCT02040090 ↗	Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects	Completed	Kamada, Ltd.	Phase 2/Phase 3	2013-04-01	The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether KamRAB interferes with the development of self active antibodies when given simultaneously with active rabies vaccine, as compared to the HRIG comparator product, also given in conjunction with the active rabies vaccine.

Clinical Trial Conditions for rabies vaccine

Condition Name

Condition Name for rabies vaccine
Intervention	Trials
Rabies	4
HIV Infections	2
Stage III Adult Hodgkin Lymphoma	1
Influenza-like Illness	1

Condition MeSH

Condition MeSH for rabies vaccine
Intervention	Trials
Rabies	11
HIV Infections	2
Respiration Disorders	1
Diarrhea	1

Clinical Trial Locations for rabies vaccine

Trials by Country

Trials by Country for rabies vaccine
Location	Trials
United States	23
Saint Kitts and Nevis	1
Mali	1
China	1
South Africa	1

Trials by US State

Trials by US State for rabies vaccine
Location	Trials
Minnesota	4
New York	3
Florida	2
North Carolina	2
Maryland	2

Clinical Trial Progress for rabies vaccine

Clinical Trial Phase

Clinical Trial Phase for rabies vaccine
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	1
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for rabies vaccine
Clinical Trial Phase	Trials
Completed	10
Active, not recruiting	2
Not yet recruiting	1

Clinical Trial Sponsors for rabies vaccine

Sponsor Name

Sponsor Name for rabies vaccine
Sponsor	Trials
Kamada, Ltd.	2
Walter Reed Army Institute of Research (WRAIR)	2
State University of New York - Upstate Medical University	2

Sponsor Type

Sponsor Type for rabies vaccine
Sponsor	Trials
Other	14
Industry	6
U.S. Fed	2